Hypoxia-activated prodrugs and (lack of) clinical progress: The need for hypoxia-based biomarker patient selection in phase III clinical trials

by Linda Spiegelberg, Ruud Houben, Raymon Niemans, Dirk de Ruysscher, Ala Yaromina, Jan Theys, Christopher P. Guise, Jeffrey B. Smaill, Adam V. Patterson, Philippe Lambin, Ludwig J. Dubois
Published 2019-02-01